Showing results (101-110 of 218) with videos related to

Sort By:
Pageof 22
The Lancet. Neurology|March 17, 2023
Family planning considerations in people with multiple sclerosisKristen M Krysko, Ruth Dobson, Raed Alroughani, et al.
JAMA Network Open|September 28, 2022
Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical TrialPatrick Vermersch, Matthew Scaramozza, Seth Levin, et al.
Journal of the Neurological Sciences|September 30, 2010
Risk factors, management and outcome of subtypes of ischemic stroke: a stroke registry from the Arabian GulfDirk Deleu, Jihad Inshasi, Naveed Akhtar, et al.
Clinical Drug Investigation|March 18, 2022
Multiple Sclerosis Relapses Following Cessation of FingolimodCharles B Malpas, Izanne Roos, Sifat Sharmin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 30, 2022
External validation of a clinical prediction model in multiple sclerosisNahid Moradi, Sifat Sharmin, Charles B Malpas, et al.
Therapeutic Advances in Neurological Disorders|April 1, 2026
Insights into adherence to cladribine tablets in the real world in multiple countries: results from patient support programsJiwon Oh, Mavis Ayer, Raed Alroughani, et al.
Multiple Sclerosis International|January 13, 2017
Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus RisksRaed Alroughani, Ayse Altintas, Mohammed Al Jumah, et al.
Multiple Sclerosis and Related Disorders|February 6, 2023
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activityTim Spelman, Dana Horakova, Serkan Ozakbas, et al.
Multiple Sclerosis and Related Disorders|November 29, 2017
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodYara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Therapeutic Advances in Neurological Disorders|February 28, 2024
Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapiesHelmut Butzkueven, Tomas Kalincik, Francesco Patti, et al.
Pageof 22